Evidence map›Paper›PMID 30649607›Full record

ArticleLangenbeck's archives of surgery2019

Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.

Hiroshi Kurahara, Hiroyuki Shinchi, Takao Ohtsuka, Yoshihiro Miyasaka, Taketo Matsunaga, Hirokazu Noshiro, Tomohiko Adachi, Susumu Eguchi, Naoya Imamura, Atsushi Nanashima and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 1 country.

Hiroshi KuraharaDigestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. h-krhr@m3.kufm.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0002-7735-9607
Hiroyuki ShinchiDigestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Takao OhtsukaSurgery and Oncology, Kyushu University, Fukuoka, 812-8582, Japan.
Yoshihiro MiyasakaSurgery and Oncology, Kyushu University, Fukuoka, 812-8582, Japan.
Taketo MatsunagaSurgery, Saga University, Saga, 849-8501, Japan.
Hirokazu NoshiroSurgery, Saga University, Saga, 849-8501, Japan.
Tomohiko AdachiSurgery, Nagasaki University, Nagasaki, 852-8501, Japan.
Susumu EguchiSurgery, Nagasaki University, Nagasaki, 852-8501, Japan.
Naoya ImamuraHepato-Biliary-Pancreas Surgery, Miyazaki University, Miyazaki, 889-1692, Japan.
Atsushi NanashimaHepato-Biliary-Pancreas Surgery, Miyazaki University, Miyazaki, 889-1692, Japan.
Kazuhiko SakamotoGastroenterological, Breast and Endocrine Surgery, Yamaguchi University, Yamaguchi, Japan.
Hiroaki NaganoGastroenterological, Breast and Endocrine Surgery, Yamaguchi University, Yamaguchi, Japan.
Masayuki OhtaGastroenterological and Pediatric Surgery, Oita University, Oita, 879-5593, Japan.
Masafumi InomataGastroenterological and Pediatric Surgery, Oita University, Oita, 879-5593, Japan.
Akira ChikamotoGastroenterological Surgery, Kumamoto University, Kumamoto, 860-0811, Japan.
Hideo BabaGastroenterological Surgery, Kumamoto University, Kumamoto, 860-0811, Japan.
Yusuke WatanabeSurgery, Kitakyushu Municipal Medical Center, Fukuoka, 802-0077, Japan.
Kazuyoshi NishiharaSurgery, Kitakyushu Municipal Medical Center, Fukuoka, 802-0077, Japan.
Masafumi YasunagaGastroenterological Surgery, Department of Medicine, Kurume University, Kurume, 830-0011, Japan.
Koji OkudaGastroenterological Surgery, Department of Medicine, Kurume University, Kurume, 830-0011, Japan.
Shoji NatsugoeDigestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Masafumi NakamuraSurgery and Oncology, Kyushu University, Fukuoka, 812-8582, Japan.
Kagoshima University · JPKyushu University · JPKitakyushu Municipal Medical Center · JPKumamoto University · JPKurume University · JPNagasaki University · JPOita University · JPSaga University · JPUniversity of Miyazaki · JPYamaguchi University · JP

Funding

No funding No number
6 · The paper itself

Abstract

purposeNeoadjuvant therapy (NAT) is increasingly used to improve the prognosis of patients with borderline resectable pancreatic cancer (BRPC) albeit with little evidence of its advantage over upfront surgical resection. We analyzed the prognostic impact of NAT on patients with BRPC in a multicenter retrospective study.

methodsMedical data of 165 consecutive patients who underwent treatment for BRPC between January 2010 and December 2014 were collected from ten institutions. We defined BRPC according to the National Comprehensive Cancer Network guidelines, and subclassified patients according to venous invasion alone (BR-PV) and arterial invasion (BR-A).

resultsThe rates of NAT administration and resection were 35% and 79%, respectively. There were no significant differences in resection rates and prognoses between patients in the BR-PV and BR-A subgroups. NAT did not have a significant impact on prognosis according to intention-to-treat analysis. However, in patients who underwent surgical resection, NAT was independently associated with longer overall survival (OS). The median OS of patients who underwent resection after NAT (53.7 months) was significantly longer than that of patients who underwent upfront (17.8 months) or no resection (14.9 months). The rates of superior mesenteric or portal vein invasion, lymphatic invasion, venous invasion, and lymph node metastasis were significantly lower in patients who underwent resection after NAT than in those who underwent upfront resection despite similar baseline clinical profiles.

conclusionsResection after NAT in patients with BRPC is associated with longer OS and lower rates of both invasion to the surrounding tissues and lymph node metastasis.

Indexed as

Neoadjuvant TherapyAdenocarcinomaCombined Modality TherapyHumansLymphatic MetastasisNeoplasm InvasivenessPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival AnalysisChemoradiotherapyChemotherapyMetastasisResection

Identifiers

PMID30649607
OpenAlexW2908681021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.